If you miss a dose due to treatment interruption, follow the guidance in the Patient Information Leaflet
The 100mg daily dose provides maximum NNMT inhibition while remaining within established safety parameters
Body composition analyses from clinical studies indicate that a portion of weight lost may be lean mass rather than fat mass
Gastrointestinal events in the SUSTAIN FORTE trial were the main side effect
Summary Keywords intermittent fasting, precision medicine, anti-obesity pharmacotherapy, cardiovascular disease, genetics, GLP-1, GIP Citation Eliopoulos AG, Gkouskou KK, Tsioufis K and Sanoudou D (2025) A perspective on intermittent fasting and cardiovascular risk in the era of obesity pharmacotherapy
The number of members on GLP-1s for weights loss is projected to grow significantly throughout the remainder of 2024 and into 2025